SIRP alpha V5/CD172a Protein, Human (HEK293, His, Avi)

The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V5/CD172a Protein, Human (HEK293, His, Avi) is the recombinant human-derived SIRP alpha V5/CD172a protein, expressed by HEK293, with C-His and C-Avi labeled tag.

SIRP alpha V4/CD172a Protein, an immunoglobulin-like cell surface receptor for CD47, acts as a docking protein that facilitates the translocation of PTPN6, PTPN11, and other binding partners from the cytosol to the plasma membrane. This receptor contributes to diverse cellular processes, including supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and facilitating glial cell attachment. With a potential role in intracellular signaling during synaptogenesis and synaptic function, SIRP alpha V4/CD172a also engages in negative regulation of receptor tyrosine kinase-coupled responses triggered by cell adhesion, growth factors, or insulin. Furthermore, it mediates the negative modulation of phagocytosis, mast cell activation, and dendritic cell activation. Notably, CD47 binding prevents the maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. SIRP alpha V4/CD172a plays a significant role in antiviral immunity, limiting new world arenavirus infection by decreasing virus internalization. As a receptor for THBS1, it participates in ROS signaling in non-phagocytic cells upon interaction with THBS1, stimulating NADPH oxidase-derived ROS production. The receptor engages in various protein interactions, including binding to PTPN11, GRB2, FGR, JAK2, SCAP1, SCAP2, FYB1, PTK2B, and TRIM2.

Human

HEK293

C-Avi;C-6*His

P78324 (E31-R370, S42F)

140885

Extracellular Domain

Approximately 50-70 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

Greater than 95% as determined by Bis-Tris PAGE.

<1 EU/μg, determined by LAL method.